• Zhichen Zhang, Xuan Wang, Jiaofeng Bai, Xiaolan Yang, Bianli Lian, Yuexia Zhang, Jin Kang, and Yaozhu Pan.
• Department of Hematology, The 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou, China.
• Medicine (Baltimore). 2024 May 10; 103 (19): e38110e38110.

RationalThe Philadelphia chromosome (Ph) is seen in most patients with chronic myeloid leukemia and some patients with acute lymphoblastic leukemia. However, Ph-positive acute myeloid leukemia (Ph + AML) is a rare entity with a poor prognosis and a short median survival period. To date, there have been few clinical reports on this disease. And the treatment regimen of this disease has not been uniformly determined.Patient ConcernsWe report a case of a Ph + AML. A 32-year-old male who was admitted to our hospital with weakness for 2 months.DiagnosisPhiladelphia chromosome-positive acute myeloid leukemia.InterventionsThe patient achieved complete remission by the administration of a tyrosine kinase inhibitor, combined with low-intensity chemotherapy and a B-cell lymphoma 2 inhibitor. Then, allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his sister was successfully performed.OutcomesThe patient has been in a continuous remission state for 6 months after transplantation.LessonsWe reported a rare Ph + AML case, successfully treated with allo-HSCT. This case provided strong support for treating Ph + AML with allo-HSCT.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

13 keywords...

hide…